Rituximab therapy in pulmonary alveolar proteinosis improves alveolar macrophage lipid homeostasis

Respiratory Research

Volumn 13, Issue , 2012, Pages

  Malur, Anagha ^a   Kavuru, Mani S ^a,b   Marshall, Irene ^a   Barna, Barbara P ^a   Huizar, Isham ^a   Karnekar, Reema ^a   Thomassen, Mary J ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

ABCG1; Alveolar macrophages; LPLA2; PAP; PPAR ; Rituximab; Surfactant

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; CHOLESTEROL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR ANTIBODY; LIPID; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHOLIPASE A2; RITUXIMAB; SURFACTANT; SURFACTANT PROTEIN A; MEMBRANE LIPID; MONOCLONAL ANTIBODY;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CATABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; LIPID ANALYSIS; LIPID HOMEOSTASIS; LIPID METABOLISM; LIPID TRANSPORT; LUNG ALVEOLUS MACROPHAGE; LUNG ALVEOLUS PROTEINOSIS; LUNG LAVAGE; MOUSE; NONHUMAN; PHASE 2 CLINICAL TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; WILD TYPE; ANIMAL; C57BL MOUSE; CLINICAL TRIAL; DRUG EFFECT; FEMALE; HOMEOSTASIS; IMMUNOLOGY; LUNG ALVEOLUS; MALE; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY;

ADULT; ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FEMALE; HOMEOSTASIS; HUMANS; MACROPHAGES, ALVEOLAR; MALE; MEMBRANE LIPIDS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PROSPECTIVE STUDIES; PULMONARY ALVEOLAR PROTEINOSIS; PULMONARY ALVEOLI;

EID: 84862227611     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-13-46     Document Type: Article

References (27)

1. Trapnell BC, Whitsett JA. GM-CSF regulates pulmonary surfactant homeostasis and alveolar macrophage-mediated innate host defense. Annu Rev Physiol 2002, 64:775-802. 10.1146/annurev.physiol.64.090601.113847, 11826288.
2. Huizar I, Kavuru MS. Alveolar proteinosis syndrome: pathogenesis, diagnosis, and management. Curr Opin Pulm Med 2009, 15:491-498. 10.1097/MCP.0b013e32832ea51c, 19561506.
3. Thomassen MJ, Yi T, Raychaudhuri B, Malur A, Kavuru MS. Pulmonary alveolar proteinosis is a disease of decreased availability of GM-CSF rather than an intrinsic cellular defect. Clin Immunol 2000, 95:85-92. 10.1006/clim.2000.4859, 10779401.
4. Carraway MS, Ghio AJ, Carter JD, Piantadosi CA. Detection of granulocyte-macrophage colony-stimulating factor in patients with pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2000, 161:1294-1299.
5. Kitamura T, Tanaka N, Watanabe J, Uchida K, Kanegasaki S, Yamada Y, Nakata K. Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor. J Exp Med 1999, 190:875-880. 10.1084/jem.190.6.875, 2195627, 10499925.
6. Tanaka N, Watanabe J, Kitamura T, Yamada Y, Kanegasaki S, Nakata K. Lungs of patients with idiopathic pulmonary alveolar proteinosis express a factor which neutralizes granulocyte-macrophage colony-stimulating factor. FEBS Lett 1999, 442:246-250. 10.1016/S0014-5793(98)01668-8, 9929010.
7. Bonfield TL, Kavuru MS, Thomassen MJ. Anti-GM-CSF titer predicts response to GM-CSF therapy in pulmonary alveolar proteinosis. Clin Immunol 2002, 105:342-350. 10.1006/clim.2002.5301, 12498816.
8. Bonfield TL, Russell D, Burgess S, Malur A, Kavuru MS, Thomassen MJ. Autoantibodies against granulocyte macrophage colony-stimulating factor are diagnostic for pulmonary alveolar proteinosis. Am J Respir Cell Mol Biol 2002, 27:481-486.
9. Seymour JF, Doyle IR, Nakata K, Presneill JJ, Schoch OD, Hamano E, Uchida K, Fisher R, Dunn AR. Relationship of anti-GM-CSF antibody concentration, surfactant protein A and B levels, and serum LDH to pulmonary parameters and response to GM-CSF therapy in patients with idiopathic alveolar proteinosis. Thorax 2003, 58:252-257. 10.1136/thorax.58.3.252, 1746613, 12612307.
10. Kitamura T, Uchida K, Tanaka N, Tsuchiya T, Watanabe J, Yamada Y, Hanaoka K, Seymour JF, Schoch OD, Doyle I, et al. Serological diagnosis of idiopathic pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2000, 162:658-662.
11. Bonfield TL, Farver CF, Barna BP, Malur A, Abraham S, Raychaudhuri B, Kavuru MS, Thomassen MJ. Peroxisome proliferator-activated receptor-gamma is deficient in alveolar macrophages from patients with alveolar proteinosis. Am J Respir Cell Mol Biol 2003, 29:677-682. 10.1165/rcmb.2003-0148OC, 12805087.
12. Thomassen MJ, Barna BP, Malur A, Bonfield TL, Farver CF, Malur A, Dalrymple H, Kavuru MS, Febbraio M. ABCG1 is deficient in alveolar macrophages of GM-CSF knock-out mice and patients with pulmonary alveolar proteinsosis. J Lipid Res 2007, 48:2762-2768. 10.1194/jlr.P700022-JLR200, 17848583.
13. Malur A, Huizar I, Wells G, Barna BP, Malur AG, Thomassen MJ. Lentivirus-ABCG1 instillation reduces lipid accumulation and improves lung compliance in GM-CSF knock-out mice. Biochem Biophys Res Commun 2011, 415:288-293. 10.1016/j.bbrc.2011.10.043, 22033401.
14. Abe A, Hiraoka M, Wild S, Wilcoxen SE, Paine R, Shayman JA. Lysosomal phospholipase A2 is selectively expressed in alveolar macrophages. J Biol Chem 2004, 279:42605-42611. 10.1074/jbc.M407834200, 15294901.
15. Abe A, Poucher HK, Hiraoka M, Shayman JA. Induction of lysosomal phospholipase A2 through the retinoid X receptor in THP-1 cells. J Lipid Res 2004, 45:667-673. 10.1194/jlr.M300342-JLR200, 14754907.
16. Grillo-Lopez AJ, White CA, Varns C, Shen D, Wei A, McClure A, Dallaire BK. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol 1999, 26:66-73.
17. Anolik J, Sanz I, Looney RJ. B cell depletion therapy in systemic lupus erythematosus. Curr Rheumatol Rep 2003, 5:350-356. 10.1007/s11926-003-0020-x, 12967516.
18. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004, 350:2572-2581. 10.1056/NEJMoa032534, 15201414.
19. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CGM, St Clair EW, Turkiewicz A, Tchao NK, et al. Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis. N Engl J Med 2010, 363:221-232. 10.1056/NEJMoa0909905, 3137658, 20647199.
20. Kavuru MS, Malur A, Marshall I, Barna BP, Meziane M, Huizar I, Dalrymple H, Karnekar R, Thomassen MJ. An Open-Label Trial of Rituximab Therapy in Pulmonary Alveolar Proteinosis. Eur Respir J 2011, 38:1361-1367. 10.1183/09031936.00197710, 21478218.
21. Malur A, Baker AD, McCoy AJ, Wells G, Barna BP, Kavuru MS, Malur AG, Thomassen MJ. Restoration of PPARgamma reverses lipid accumulation in alveolar macrophages of GM-CSF knockout mice. Am J Physiol Lung Cell Mol Physiol 2011, 300:L73-L80. 10.1152/ajplung.00128.2010, 21036914.
22. Thomassen MJ, Buhrow LT, Connors MJ, Kaneko FT, Erzurum SC, Kavuru MS. Nitric oxide inhibits inflammatory cytokine production by human alveolar macrophages. Am J Respir Cell Mol Biol 1997, 17:279-283.
23. Iyonaga K, Suga M, Yamamoto T, Ichiyasu H, Miyakawa M, Ando M. Elevated bronchoalveolar concentrations of MCP-1 in patients with pulmonary alveolar proteinosis. Eur Respir J 1999, 14:383-389.
24. Dranoff G, Crawford AD, Sadelain M, Ream B, Rashid A, Bronson RT, Dickersin GR, Bachurski CJ, Mark EL, Whitsett JA, et al. Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science 1994, 264:713-716. 10.1126/science.8171324, 8171324.
25. Malur A, Mccoy AJ, Arce S, Barna BP, Kavuru MS, Malur AG, Thomassen MJ. Deletion of PPARγ in alveolar macrophages is associated with a Th-1 pulmonary inflammatory response. J Immunol 2009, 182:5816-5822. 10.4049/jimmunol.0803504, 19380830.
26. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408. 10.1006/meth.2001.1262, 11846609.
27. Kennedy MA, Barrera GC, Nakamura K, Baldan A, Tarr P, Fishbein MC, Frank J, Francone OL, Edwards PA. ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell Metab 2005, 1:121-131. 10.1016/j.cmet.2005.01.002, 16054053.